Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients.

Neuroscience journal Pub Date : 2017-01-01 Epub Date: 2017-11-08 DOI:10.1155/2017/5629563

Ave Minajeva, Marju Kase, Mikk Saretok, Aidi Adamson-Raieste, Sandra Kase, Kristi Niinepuu, Markus Vardja, Toomas Asser, Jana Jaal

{"title":"Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients.","authors":"Ave Minajeva, Marju Kase, Mikk Saretok, Aidi Adamson-Raieste, Sandra Kase, Kristi Niinepuu, Markus Vardja, Toomas Asser, Jana Jaal","doi":"10.1155/2017/5629563","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GB) is the most angiogenic tumor. Nevertheless, antiangiogenic therapy has not shown significant clinical efficacy. The aim of this study was to assess blood vessel characteristics on survival of GB patients. Surgically excised GB tissues were histologically examined for overall proportion of glomeruloid microvascular proliferation (MP) and the total number of blood vessels. Also, immunohistochemical vascular staining intensities of CD133 and ICAM-1 were determined. Vessel parameters were correlated with patients' overall survival. The survival time depended on the number of blood vessels (p = 0.03) but not on the proportion of MP. Median survival times for patients with low (<median) and high (≥median) number of blood vessels were 9.0 months (95% CI: 7.5-10.5) and 12.0 months (95% CI: 9.3-14.7). Also, median survival times for patients with low (<median) and high (≥median) vascular expression level of CD133 were 9.0 months (95% CI: 8.0-10.1) and 12.0 months (95% CI: 10.3-13.7). In contrast, the staining intensity of vascular ICAM-1 did not affect survival. In multivariate analysis, the number of blood vessels emerged as an independent predictor for longer overall survival (HR: 2.4, 95% CI: 1.2-5.0, p = 0.02). For success in antiangiogenic therapy, better understanding about tumor vasculature biology is needed.","PeriodicalId":91144,"journal":{"name":"Neuroscience journal","volume":"2017 ","pages":"5629563"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/5629563","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/5629563","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/11/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

Abstract

Glioblastoma (GB) is the most angiogenic tumor. Nevertheless, antiangiogenic therapy has not shown significant clinical efficacy. The aim of this study was to assess blood vessel characteristics on survival of GB patients. Surgically excised GB tissues were histologically examined for overall proportion of glomeruloid microvascular proliferation (MP) and the total number of blood vessels. Also, immunohistochemical vascular staining intensities of CD133 and ICAM-1 were determined. Vessel parameters were correlated with patients' overall survival. The survival time depended on the number of blood vessels (p = 0.03) but not on the proportion of MP. Median survival times for patients with low (p = 0.02). For success in antiangiogenic therapy, better understanding about tumor vasculature biology is needed.

Abstract Image

查看原文本刊更多论文

血管数量及血管CD133和ICAM-1表达对胶质母细胞瘤患者生存的影响

胶质母细胞瘤(GB)是血管生成能力最强的肿瘤。然而，抗血管生成治疗尚未显示出显著的临床疗效。本研究的目的是评估血管特征对GB患者生存的影响。对手术切除的GB组织进行组织学检查，观察肾小球微血管增生(glomerulloid microvascular proliferation, MP)总比例和血管总数。同时测定CD133和ICAM-1的免疫组化血管染色强度。血管参数与患者总生存期相关。存活时间与血管数目有关(p = 0.03)，与MP比例无关。患者中位生存时间较低(p = 0.02)。为了抗血管生成治疗的成功，需要更好地了解肿瘤血管生物学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroscience journal

自引率

0.00%

发文量